z-logo
open-access-imgOpen Access
Rosiglitazone Revisited
Author(s) -
Steven E. Nissen,
Kathy Wolski
Publication year - 2010
Publication title -
archives of internal medicine
Language(s) - English
Resource type - Journals
eISSN - 1538-3679
pISSN - 0003-9926
DOI - 10.1001/archinternmed.2010.207
Subject(s) - rosiglitazone , medicine , odds ratio , confidence interval , randomized controlled trial , myocardial infarction , context (archaeology) , insulin , paleontology , biology
Controversy regarding the effects of rosiglitazone therapy on myocardial infarction (MI) and cardiovascular (CV) mortality persists 3 years after a meta-analysis initially raised concerns about the use of this drug.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom